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Abstract
Objective: Over 200 genes have been reported to be associated 
with osteoarthritis (OA), but most of them have not been replicated 
in an independent sample. Using the newly collected cohort from a 
genetically isolated population - the Newfoundland and Labrador 
population, we attempted to replicate 105 previously reported OA-
associated SNPs.
Methods: A case-control study design was utilized in this study. 
Patients undergoing total hip/knee joint replacements due to severe 
OA were collected as cases. A group of healthy individuals with no 
evidence of OA was used as control.105 SNPs were genotyped either 
by Sequenom iPLEX Gold method or Illumina GWAS genotyping 
platform. The cross-reference was performed on both methods in a 
subset of samples for genotyping quality control. A logistic regression 
model was used to test for associations between the SNPs and OA.
Results: A total of 126 cases and 348 healthy controls were 
included in the final analysis. OA Patients were on average 9 years 
older than healthy controls (p<0.0001), but there was no difference in 
BMI. We were unable to replicate the previously reported associations. 
Two SNPs, rs2294995 (COL9A3), and rs1049007 (BMP2) showed an 
association with p<0.05, but the significance did not survive the 
Bonferroni multiple testing correction. 
Conclusion: A lack of replication might be due to study design, 
complexity of OA, method of OA ascertainment, populations studied, 
or false positives in the original publications. A study with larger sample 
is needed to confirm the two possible SNPs with OA.
Introduction
Osteoarthritis (OA) is the most common form of arthritis causing 
joint pain, stiffness, limited range of motion, joint deformity, and 
disability [1]. Its prevalence is on the rise due to population aging and 
increasing prevalence in obesity. Knee, hip, hand, spine, and foot are 
the most affected joints while the greatest public health burden results 
from hip and/or knee OA [2]. To date, there are no drugs available for 
rebuilding the damaged cartilage, nor is there a clear understanding 
of the pathogenesis of the disease. Total joint replacement therapy is 
the only choice for people with advanced OA. In the US alone, the 
total number of hip and/or knee joint replacement surgery due to OA 
is 350,000 each year [3], and the annual per person cost of those living 
with OA has been estimated to be around $5700 [4]. Arthritis, mostly 
OA, costs $128 million per year in medical care and other indirect 
expenses including those resulting from work limitation and loss of 
productivity in the US [5].
Although the etiology of OA is not completely understood, it 
is believed that OA is a multifactorial condition developing and 
progressing as a result of a combination of different environmental 
and genetic factors [6]. The main environmental risk factors include 
age, gender, obesity, previous joint injury, and joint mal-alignments 
[7]. Evidence suggests a strong genetic component to OA; from twin 
studies this genetic influence has been estimated to be between 40% 
and 65% for knee, hip [8], and hand OA [9], and first-degree relatives 
of individuals with spine, hand, hip, or polyarticular OA have a two- 
to three-fold increased risk of the disease [10,11].
To date, 9 Genome-Wide Association Studies (GWAS), along 
with a large number of candidate gene studies and linkage analyses, 
have been performed on OA. Although some OA-associated genes 
such as GDF5 have been replicated in independent studies, the 
majority of the studied loci have inconsistent results [12]. This might 
be due to genetic heterogeneous nature of the disease or false positive 
findings in the initial studies. Genetically isolated populations have 
advantages for complex disease gene mapping because of their reduced 
genetic heterogeneity and extended LD [13]. The Newfoundland and 
Labrador population is a young isolated founder population with 
a high degree of both genetic and cultural homogeneity exhibiting 
extended linkage disequilibrium and an increased kinship coefficient, 
which provides a unique source for investigating both single gene 
diseases and complex traits [14,15]. Using this unique population, 
the aim of the present study was to replicate previously reported OA-
associated genes. 
Methods and Materials
Subjects
The study was part of the Newfoundland Osteoarthritis Study 
(NFOAS) that was initiated in 2011 and aimed at identifying 
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novel genetic, epigenetic, and biochemical markers for OA. OA 
patients were recruited from those who underwent total knee or 
hip replacement surgery due to primary OA between Nov. 2011 to 
Jun. 2013 in St. Clare’s Mercy Hospital and Health Science Centre 
General Hospital in St. John’s, the capital city of Newfoundland and 
Labrador (NL) province of Canada. A group of healthy people who 
do not have any evidence of either knee or hip OA were used as 
controls. The controls were selected from previous genetic association 
study for type 2 diabetes and obesity. The controls completed a 
questionnaire regarding any ongoing symptoms, previous diagnosis 
and medication history. Each patient was also examined by a 
rheumatologist. The controls were selected for this study if they had 
no musculoskeletal pain, a prior diagnosis of osteoarthritis, were 
not taking acetaminophen or NSAIDs and had a normal physical 
examination, as it relates to the skeletal system. All cases and controls 
in this study were from NL. The study was approved by Health 
Research Ethics Authority (HREA) of Newfoundland and Labrador 
and a written consent was obtained from all the participants.
Height and weight measurements were obtained from patient’s 
hospital medical record. Body mass index (BMI) was calculated as 
weight in kilogram divided by squared height in meters. Age was 
calculated for the time of surgery or visit date.
Genotyping
HuGE Navigator [16], a continuously updated database in human 
genome epidemiology, indexes all of the genetic association studies 
for a given disease or trait. There were 231 genes reported to be 
associated with OA as of June 2013. Due to limited budget, we chose 
to replicate all the SNPs that were reported in OA GWAS studies plus 
some SNPs from candidate studies. 
Blood samples were obtained from all study participants and 
DNA was extracted by using the standard protocol. All the OA cases 
were genotyped by Sequenom iPLEX Gold method [17]. Briefly, 
384-well plate chip on Sequenom using mass spectrometry was used 
for genotyping. Each multiplex PCR was done using 30ng of DNA 
(n=1: 1.25X PCR buffer Roche, 2mM MgCl2 Roche, 0.5M dNTPs, 
0.11uM PCR primer pool oligos ordered from IDT, 0.15U/uL Roche 
FastStart) and the amplification was done following this cycling 
protocol: [95c 15min, 45x (95c 20sec, 58c 30sec, 72c 60sec), 72c 
3min]. The SAP reaction was done to clean the PCR product and is 
followed by the extension reaction. After extension, the Salt Adduct 
Removal Step was run using 6mg of resin. The product was then spot 
on a Sequenom 384-well chip using a Nanodispenser, and loaded 
onto the Mass Spectrometer for reading.
All the controls were previously genotyped using Illumina 
HumanHap550-Duo BeadChip at Centrillion Biosciences at Palo 
Alto, California. 
Cross-validation of genotyping quality was carried out on 31 
controls that were genotyped by both Sequenom iPLEX Gold method 
and IlluminaHumanHap550-Duo BeadChip. 
Statistical analysis
Distribution of age, gender, and BMI was examined and tested 
between OA cases and controls by either Chi-squared test or 
Student t-test wherever appropriate. Genotyping accuracy between 
two genotyping methods was evaluated by calculating genotype 
concordance rate in those subjects who were genotyped by both 
methods. Hardy-Weinberg Equilibrium (HWE) test was performed 
for each of the SNPs by exact Chi-squared test and removed in the 
subsequent analysis if p value <0.05. Chi-squared test was utilized to 
test the association between each of the SNPs and OA and logistic 
regression modeling was used to adjust for potential confounders 
including age, sex, and BMI. Significance level was set at alpha level 
of 0.0007 after correcting multiple testing with Bonferroni method. 
All analyses were done using STATA/SE 11.2 (Stata Corp, College 
Station, Texas, USA) except for HWE test which was performed by 
PLINK version 1.07 [18].
Results
A total of 126 OA cases and 348 controls were included in this 
study. Among OA cases, 50 were males and 76 were females, 42 had 
total hip replacement and 84 had total knee replacement due to 
primary OA. Controls (146 males and 202 females) are healthy 
subjects who did not have evidence of joint OA. Characteristics of 
the study participants are presented in Table 1. OA cases were 
significantly older than healthy controls, and had a slightly higher 
BMI, which was not significant. 
105 SNPs located in 71 genes were genotyped by Sequenom 
iPLEX Gold method for all cases and 52 healthy controls. 69 of these 
105 SNPs were included in Illumina HumanHap550-Duo BeadChip 
and genotyped for all controls and therefore the subsequent analysis 
was focused on these 69 SNPs. 31 healthy controls were genotyped 
by both methods and were used to cross-validate the genotyping 
quality and accuracy between two genotyping methods. The genotype 
concordance rates for all 69 SNPs were 100%, indicating the 
comparability and accuracy of the two genotyping methods. 
Two SNPs were deviated from HWE and excluded from the 
subsequent analyses. Table 2 presents the results of the univariable 
and multivariable analysis of the association of each of the SNPs 
between OA and healthy controls. We found that minor alleles of 
rs2294995 located in COL9A3 and rs1049007 located in BMP2 were 
associated with one-third reduced risk for OA, but the significance 
did not survive the Bonferroni correction for multiple testing.
In the joint specific analyses, three SNPs were associated with 
knee OA [COL9A3 rs2294995 (OR:0.51, 95%CI: 0.32-0.8, P=0.004), 
HFE rs1799945 (OR:1.67, 95%CI: 1.06-2.6, P=0.025), and PACE4 
rs900414 (OR:0.63, 95%CI: 0.41-0.97, P=0.036)], and five SNPs with 
hip OA [EDG2 rs10980705 (OR:0.4, 95%CI: 0.19-0.89, P=0.024), 
IL1RN rs315952 (OR:0.5, 95%CI: 0.26-0.93, P=0.03), BMP2 rs1049007 
(OR:0.56, 95%CI: 0.33-0.95, P=0.03), IL1RN rs9005 (OR:1.69, 95%CI: 
1.03-2.78, P=0.038), and COX2 rs5277 (OR:1.74, 95%CI: 1-3.01, 
Variables OA (n=126)
Healthy 
Controls (n=348) P-value
¶
Age (yr) 63.8±0.87 54.8±0.81 <0.0001
BMI (kg/m2) 33.05±0.67 31.7±0.39 0.07
Sex (% female) 60.3% 58.1% 0.65
Table 1:  Descriptive statistics of the study population*.
* Figures stand for Mean ± SE unless stated. ¶P-value for comparison between 
OA cases and healthy controls.
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Risk 
Allele
Univariable Multivariable Risk allele Freq.
Gene SNP OR (95% CI) P-value OR (95% CI) P-value Controls Cases
BMP2 rs1049007 (A/G) A 0.69 (0.5 - 0.94) 0.021* 0.64 (0.45 - 0.9) 0.011* 0.43 0.35
COL9A3 rs2294995 (A/G) A 0.64 (0.46 - 0.9) 0.010* 0.65 (0.46 - 0.94) 0.021* 0.33 0.24
TLR8 rs5744080 (T/C) T 1.2 (0.94-1.53) 0.130 1.31 (1.00-1.71) 0.040* 0.41 0.48
PACE4 rs900414 (A/G) A 0.76 (0.54 - 1.06) 0.109 0.7 (0.48 - 1.01) 0.060 0.31 0.26
MTHFR rs1801133 (A/G) A 1.32 (0.98 - 1.78) 0.068 1.36 (0.98 - 1.89) 0.065 0.31 0.38
ADAM12 rs1871054 (A/G) G 1.2 (0.9 - 1.61) 0.219 1.33 (0.96 - 1.85) 0.085 0.46 0.50
IL18 rs1946518 (A/C) A 1.15 (0.85 - 1.55) 0.363 1.33 (0.95 - 1.85) 0.097 0.40 0.44
DIO3 rs945006 (A/C) C 0.81 (0.52 - 1.26) 0.356 0.69 (0.43 - 1.13) 0.139 0.15 0.12
ADAM12 rs3740199 (C/G) C 1.26 (0.95 - 1.68) 0.107 1.25 (0.91 - 1.7) 0.163 0.47 0.53
ADAM12 rs1044122 (A/G) A 1.21 (0.88 - 1.67) 0.234 1.26 (0.89 - 1.78) 0.196 0.23 0.27
IL4R rs2234895 (C/T) T 0.7 (0.38 - 1.28) 0.244 0.65 (0.34 - 1.25) 0.199 0.08 0.06
PTGS2/COX-2 rs20417 (C/G) G 1.23 (0.82 - 1.83) 0.319 1.33 (0.86 - 2.06) 0.201 0.15 0.18
ASTN2 rs4836732 (C/T) C 1.19 (0.89 - 1.58) 0.243 1.22 (0.9 - 1.66) 0.208 0.48 0.53
HFE rs1799945 (C/G) C 1.3 (0.89 - 1.91) 0.178 1.3 (0.86 - 1.96) 0.214 0.15 0.19
DIO2 rs225014 (C/T) T 1.27 (0.95 - 1.69) 0.108 1.22 (0.89 - 1.67) 0.214 0.36 0.42
IL6 rs1800797 (A/G) A 0.78 (0.58 - 1.05) 0.098 0.82 (0.6 - 1.13) 0.228 0.41 0.35
IL6 rs1800796 (G/C) G 0.7 (0.35-1.38) 0.310 0.6 (0.32-1.31) 0.230 0.05 0.04
GLTBD1 rs6976 (C/T) C 0.89 (0.66 - 1.2) 0.447 0.82 (0.6 - 1.13) 0.230 0.41 0.38
IL1B rs1143633 (A/G) A 1.18 (0.88 - 1.58) 0.272 1.2 (0.87 - 1.64) 0.260 0.34 0.38
COX2 rs5277 (C/G) G 1.14 (0.77 - 1.67) 0.518 1.26 (0.82 - 1.93) 0.285 0.15 0.17
IL1B rs1143634 (C/T) T 0.88 (0.63 - 1.25) 0.485 0.83 (0.57 - 1.19) 0.305 0.23 0.21
VDR rs731236 (C/T) T 1.16 (0.87 - 1.55) 0.302 1.17 (0.85 - 1.6) 0.329 0.42 0.46
IL1RN rs315952 (A/G) G 0.83 (0.59 - 1.15) 0.255 0.84 (0.59 - 1.19) 0.332 0.28 0.25
ESR1/alpha rs2234693 (G/A) G 0.8 (0.61-1.06) 0.130 0.87 (0.64-1.18) 0.370 0.46 0.40
ANP32A rs7164503 (A/G) G 0.92 (0.57 - 1.49) 0.737 0.79 (0.47 - 1.33) 0.375 0.11 0.1
HLA class II/III rs7775228 (A/G) G 1.2 (0.77 - 1.86) 0.414 1.22 (0.75 - 1.99) 0.417 0.11 0.13
DIO2 rs12885300 (A/G) A 0.82 (0.6 - 1.12) 0.222 0.87 (0.62 - 1.22) 0.421 0.36 0.32
EDG2 rs10980705 (A/G) G 0.82 (0.58 - 1.16) 0.256 0.86 (0.59 - 1.25) 0.427 0.23 0.19
CHST11 rs835487 (A/G) A 0.84 (0.62 - 1.15) 0.280 0.87 (0.62 - 1.22) 0.431 0.36 0.32
IL1A rs1800587 (A/G) A 0.94 (0.69 - 1.3) 0.727 0.88 (0.62 - 1.25) 0.473 0.29 0.28
Matrilin3 rs8176070 (C/T) C 0.95 (0.7 - 1.29) 0.755 0.89 (0.63 - 1.25) 0.496 0.35 0.34
SUPT3H/CDC5L rs10948172 (A/G) G 0.87 (0.63 - 1.2) 0.406 0.89 (0.63 - 1.26) 0.504 0.31 0.28
pTGS2/ PLA2G4A rs4140564 (C/T) C 1.56 (0.87 - 2.81) 0.137 1.24 (0.65 - 2.35) 0.515 0.05 0.08
LRCH1 rs912428 (A/G) A 1.06 (0.74 - 1.52) 0.745 1.13 (0.77 - 1.68) 0.532 0.20 0.21
IL18R1/IL18RAP rs2287037 (C/T) T 1.05 (0.78 - 1.42) 0.743 1.11 (0.8 - 1.54) 0.539 0.35 0.36
IL1B rs16944 (A/G) A 1.03 (0.76 - 1.4) 0.835 1.11 (0.79 - 1.55) 0.543 0.34 0.35
TLR-3 rs3775296 (G/T) T 1.03 (0.72 - 1.48) 0.868 1.12 (0.77 - 1.65) 0.549 0.18 0.18
IL4 rs2070874 (C/T) T 0.89 (0.58 - 1.37) 0.598 0.87 (0.53 - 1.42) 0.566 0.13 0.12
MCF2L rs11842874 (A/G) G 0.87 (0.52 - 1.46) 0.592 0.86 (0.5 - 1.48) 0.580 0.09 0.08
CALM2 rs10153674 (A/G) A 0.98 (0.65 - 1.48) 0.917 0.88 (0.56 - 1.39) 0.587 0.15 0.14
A2BP1 rs716508 (C/T) T 1.12 (0.82 - 1.53) 0.461 1.09 (0.77 - 1.54) 0.615 0.31 0.34
FTO rs8044769 (C/T) C 0.83 (0.62 - 1.11) 0.208 0.92 (0.67 - 1.27) 0.621 0.48 0.43
HLA class II/III rs10947262 (A/G) A 1.2 (0.68 - 2.13) 0.530 1.16 (0.63 - 2.15) 0.632 0.06 0.07
TXNDC3 rs4720262 (C/T) T 0.88 (0.64 - 1.22) 0.452 0.92 (0.65 - 1.3) 0.634 0.28 0.26
ADAMTS5 rs2380585 (A/G) A 0.93 (0.65 - 1.34) 0.701 0.91 (0.62 - 1.36) 0.658 0.21 0.2
TLR-9 rs187084 (A/G) G 1.01 (0.76 - 1.35) 0.928 0.93 (0.68 - 1.28) 0.673 0.41 0.41
Table 2: Results of the association test for each SNP between OA cases and healthy controls.*
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IL1RN rs419598 (A/G) G 1.02 (0.74 - 1.39) 0.922 0.93 (0.66 - 1.31) 0.691 0.30 0.3
GDF5/ASPN rs13301537 (C/T) C 1.03 (0.75 - 1.42) 0.840 1.07 (0.76 - 1.52) 0.698 0.28 0.28
ESR2/beta rs1256031 (C/T) T 1.16 (0.86 - 1.56) 0.335 1.06 (0.77 - 1.47) 0.717 0.45 0.48
TRPV1 rs8065080 (A/G) A 0.98 (0.72 - 1.32) 0.875 0.94 (0.68 - 1.31) 0.724 0.38 0.38
TNF-A rs1800629 (A/G) A 0.94 (0.64 - 1.39) 0.765 0.93 (0.61 - 1.41) 0.738 0.18 0.17
IL4R rs1805013 (A/G) A 1.09 (0.49 - 2.42) 0.838 0.87 (0.36 - 2.09) 0.760 0.03 0.04
AACT rs4934 (C/T) T 0.91 (0.68 - 1.21) 0.501 0.96 (0.7 - 1.31) 0.800 0.48 0.46
IL1R1 rs1465325 (C/T) C 0.95 (0.65 - 1.4) 0.808 0.95 (0.62 - 1.44) 0.802 0.17 0.17
LEP rs2060715 (A/G) A 0.85 (0.63 - 1.13) 0.264 0.96 (0.7 - 1.32) 0.808 0.48 0.44
TP63 rs12107036 (A/G) A 1.04 (0.78 - 1.38) 0.795 1.03 (0.76 - 1.42) 0.832 0.48 0.49
ESR1/alpha rs2228480 (C/T) T 0.89 (0.62 - 1.27) 0.513 0.96 (0.65 - 1.41) 0.835 0.22 0.2
NFKB1A rs8904 (C/T) C 0.96 (0.7 - 1.33) 0.820 0.97 (0.69 - 1.38) 0.871 0.31 0.31
HAPLN1 rs179851 (C/T) C 0.92 (0.67 - 1.25) 0.588 1.03 (0.74 - 1.44) 0.873 0.32 0.31
LEP rs12706832 (C/T) T 0.86 (0.64 - 1.15) 0.303 0.97 (0.71 - 1.34) 0.875 0.47 0.44
IL1RN rs9005 (C/T) C 1.09 (0.8 - 1.49) 0.577 1.02 (0.73 - 1.43) 0.909 0.31 0.33
RAGE rs2070600 (A/G) A 1.39 (0.77 - 2.5) 0.280 1.04 (0.52 - 2.07) 0.921 0.05 0.07
COL2A1 rs2070739 (C/T) T 0.92 (0.57 - 1.47) 0.720 0.98 (0.59 - 1.62) 0.922 0.11 0.1
UQCC rs6087704 (A/G) G 1.02 (0.75 - 1.37) 0.911 1.02 (0.73 - 1.41) 0.926 0.35 0.35
WISP1 rs2929970 (C/T) C 0.99 (0.74 - 1.32) 0.952 0.99 (0.72 - 1.36) 0.958 0.49 0.49
ESR2/beta rs1256049 (C/T) T 0.69 (0.28 - 1.69) 0.418 0.98 (0.38 - 2.55) 0.973 0.03 0.02
GDF5 rs224329 (C/T) T 1.01 (0.74 - 1.36) 0.964 1.00 (0.72 - 1.39) 1.000 0.34 0.34
P=0.048)], but all the significance did not survive the Bonferroni 
multiple testing correction.
Discussion
The study is one of the few efforts on the replication of the 
previously identified genetic variants in OA. Advantages of the 
current study include using a genetically homogeneous population 
and advanced OA cases. The reduced genetic heterogeneity and using 
advanced OA cases are believed to increase study power in genetic 
association test.
Although we were unable to replicate any of the SNPs that 
were previously reported to be associated with OA with a stringent 
significance level, two SNPs showed a potential to be associated with 
OA. One is rs2292995 located in COL9A3, which is a structure gene 
of articular cartilage. The gene has been associated with multiple 
epiphyseal dysplasia type 3 [19], and primary OA [20]. The second 
SNP is rs1049007 located in BMP2, which is involved in TGF-β 
signalling pathway that has been implicated in OA [21]. Although the 
associations for these SNPs did not reach the Bonferroni corrected 
significance level, it warrants further investigation in a large sample.
SNP rs143383 located in GDF5 gene is by far the most replicated 
SNP that is associated with OA. It was initially discovered in Asian 
population [22], followed by replication studies in European 
populations [23], and several meta-analyses confirmation [24,25]. The 
SNP was not included in the Illumina GWAS genotyping platform 
we used but we have a proxy SNP rs224329 which has r2=0.92 with 
rs143383. However, we could not detect any association between 
rs224329 and OA. Small sample size in the current study might be 
a possible explanation, but the results are the same as in the recent 
large GWAS on OA performed in the UK population [26], in which 
over 7410 OA cases and 11,009 unrelated population controls were 
included. Given the genetic similarity between Newfoundland and 
Labrador population and British population, the results may suggest 
the GDF5-OA association is population specific.
Data on replication of previously reported OA-associated genes 
are limited. GOAL study [27] utilized large number of symptomatic 
radiographic knee or hip OA and controls to replicate 68 variants in 
12 genes including IL1A, IL1B, IL1RN, IL4R, IL6, COL2A1, ADAM12, 
ASPN, IGF1, TGFB1, ESR1 and VDR, but they did not replicate any of 
these associations. All the genetic variants they studied were included 
in our study. Similarly, these SNPs were not associated with OA in 
our sample; neither did in the large genome-wide meta-analysis [28].
Failure in the replication of previously reported genetic 
associations is common to the point that only less than 5% of the 
reported associations could be replicated in an independent study 
[29], which along with other factors has raised criticism on the 
usefulness of association studies [30]. The reasons for the failures are 
numerous: initially reported associations might be false positives, or 
replications might be false negative findings resulting from a biased 
sampling, hidden or uncorrected population stratification, small 
sample sizes. The association might only hold true for the population 
in which the association was reported due to the differences and 
specificity of LD patterns across different populations. The complexity 
of multifactorial traits is another issue: the effect of multiple genetic 
variants and heterogeneity means that the presence of all of the 
risk alleles together may not be required for the disease to develop; 
therefore, distribution of risk alleles in two groups of cases from 
different or even same population might be different from each other. 
All these factors are aggravated in the study of OA due to the age 
dependency and the lack of a unique method for the ascertainment of 
the study subjects used by different investigators.
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The above-mentioned reasons could partially explain why we 
were not able to replicate the majority of the SNPs in our study. In 
addition, our study has been limited by a number of factors: sample 
size is relatively small. Given our sample size and assuming minor 
allele frequency of 35% in controls, we have 80% power to only 
detect an OR of 1.8 or above at an alpha level of 0.05. The minimum 
detectable OR would be 2.5 if we define the significance level at 0.0007 
after taking into account of multiple testing. However, the study 
power is maximized by the optimal case-control ratio and using 
extreme severe OA cases. We recently found that NL population has 
slightly subtle population stratification (not published data), which 
might lead to false negatives. 
In conclusion, we were unable to replicate the previously reported 
OA-associated genes, but two SNPs showed suggestive associations 
with plausible biological mechanism. Further studies are needed to 
confirm the results.  
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